Worcester, MA. – Agilux Laboratories, a key provider of pharmaceutical and biotech drug discovery and development services, is pleased to announce its recent purchase of two AB SCIEX Triple Quad 6500 LC-MS/MS Systems, designed to provide even greater levels of sensitivity and increased limits of quantitation to its bioanalytical services in support of pharmacokinetic (PK) studies. These advanced systems will further enhance the range of LC-MS/MS capabilities for its clients’ discovery and development programs.

As an early adopter of these state-of-the-art mass spectrometers in the New England area, Agilux continues to implement the most advanced technologies for its growing facilities and research capabilities.

“We continually strive to deliver the most cutting-edge systems for our clients’ programs and remain focused on the quality of their critical data needs and timelines,” said Steve Guyan, Vice President, Sales and Marketing. “By combining the latest LC-MS/MS technologies, such as the AB Sciex Triple Quad 6500 System, with our expert research and rapid turnaround times, are what make us a first choice in our clients’ discovery and development programs.”

“The AB SCIEX 6500 Series represents a quantum leap forward in mass spectrometry quantitation,” said Rainer Blair, President of AB SCIEX. “With the first-of-its-kind IonDrive technology that we are pioneering in the new AB SCIEX 6500 System, scientists will be able to quantitate at lower concentration levels than ever before. This is truly game-changing technology, and we expect it to help reinforce AB SCIEX’s market leadership.”